(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Vera Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast VERA's revenue for 2025 to be $545,132,084, with the lowest VERA revenue forecast at $545,132,084, and the highest VERA revenue forecast at $545,132,084. On average, 3 Wall Street analysts forecast VERA's revenue for 2026 to be $2,798,676,592, with the lowest VERA revenue forecast at $512,247,150, and the highest VERA revenue forecast at $6,733,805,611.
In 2027, VERA is forecast to generate $8,216,061,511 in revenue, with the lowest revenue forecast at $3,879,011,668 and the highest revenue forecast at $13,823,565,048.